Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (211-220 of 266) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Journal of the National Cancer Institute|January 27, 2017
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer PatientsEnrique Gonzalez-Billalabeitia, Daniel Castellano, Nora Sobrevilla, et al.
The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell CarcinomaXiaoyan Liu, Jesse J Swen, Meta H M Diekstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of <i>RB1</i> StatusCarolina Rubio, Mónica Martínez-Fernández, Cristina Segovia, et al.
World Journal of Gastroenterology|December 11, 2025
<i>Dialister</i>-driven succinate accumulation is associated with disease activity and postoperative recurrence in Crohn's diseaseAlbert Boronat-Toscano, Maria Isabel Queipo-Ortuño, Diandra Monfort-Ferré, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
European Urology Oncology|September 11, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b TrialMaria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, et al.
Pageof 27

Showing results (211-220 of 266) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Journal of the National Cancer Institute|January 27, 2017
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer PatientsEnrique Gonzalez-Billalabeitia, Daniel Castellano, Nora Sobrevilla, et al.
The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell CarcinomaXiaoyan Liu, Jesse J Swen, Meta H M Diekstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of <i>RB1</i> StatusCarolina Rubio, Mónica Martínez-Fernández, Cristina Segovia, et al.
World Journal of Gastroenterology|December 11, 2025
<i>Dialister</i>-driven succinate accumulation is associated with disease activity and postoperative recurrence in Crohn's diseaseAlbert Boronat-Toscano, Maria Isabel Queipo-Ortuño, Diandra Monfort-Ferré, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
European Urology Oncology|September 11, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b TrialMaria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, et al.
Pageof 27